EGFR and neoplasm: Overexpression of β-galactoside α-2,6-sialyltransferase, which increases α-2,6 sialylation of EGFR, has been linked to poor prognosis of cancers [29] and has been implicated in promoting tumor cell proliferation and drug resistance in some cancers [16,17].